Mhairi Maskew to Tenofovir
This is a "connection" page, showing publications Mhairi Maskew has written about Tenofovir.
Connection Strength
0,632
-
Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa. Trop Med Int Health. 2018 06; 23(6):650-660.
Score: 0,144
-
Changes in elevated cholesterol in the era of tenofovir in South Africa: risk factors, clinical management and outcomes. HIV Med. 2017 09; 18(8):595-603.
Score: 0,133
-
Tenofovir stock shortages have limited impact on clinic- and patient-level HIV treatment outcomes in public sector clinics in South Africa. Trop Med Int Health. 2017 02; 22(2):241-251.
Score: 0,131
-
Tenofovir use and pregnancy among women initiating HAART. AIDS. 2012 Nov 28; 26(18):2393-7.
Score: 0,099
-
Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir. Trop Med Int Health. 2014 May; 19(5):490-8.
Score: 0,027
-
Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa. J Int AIDS Soc. 2013 Nov 19; 16:18794.
Score: 0,026
-
The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa. PLoS One. 2013; 8(8):e71719.
Score: 0,026
-
The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. HIV Med. 2013 Apr; 14(4):217-25.
Score: 0,024
-
Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS. 2011 Aug 24; 25(13):1603-9.
Score: 0,023